1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors - Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...